{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-011627","form_type":"8-K","ticker":"CVM","cik":"0000725363","company_name":"CEL SCI CORP","filed_at":"2022-08-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.022068+00:00","generated_at":"2026-06-23T22:23:18.614637+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"CEL-SCI Phase 3 Multikine shows 14.1% 5-year OS benefit in lower-risk head and neck cancer","bullets":["8.1% ORR for Multikine+CIZ vs 0% SOC in ITT; 15.2% ORR in proposed indication (n=158).","14.1% absolute OS advantage at 5 years in lower-risk arm (62.7% vs 48.6%; HR=0.68).","Median OS nearly 4 years longer: 101.7 months vs 55.2 months for SOC in proposed indication.","No excess safety issues; adverse event rates similar across all treatment arms.","Company plans to submit BLA to FDA for indication covering ~210,000 patients globally."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-011627","json":"https://secwatch.observer/filing/0001654954-22-011627.json","markdown":"https://secwatch.observer/filing/0001654954-22-011627.md","text":"https://secwatch.observer/filing/0001654954-22-011627.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/725363/000165495422011627/0001654954-22-011627-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/725363/000165495422011627/cvm_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T22:23:18.614637+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}